Spero Therapeutics Announces Third Quarter 2026 Operating Results and Provides Business Update
Key Highlights
- ➤Cash $107.9M, expected to fund operations into the second half of 2029
- ➤SP001 Phase 2 IgG4-RD study planned for Q2 2027
- ➤Spero secured $105M non-recourse, non-dilutive milestone and royalty financing
- ➤Q3 net loss $44.3M, versus $7.4M loss in 2025
- ➤Q3 R&D expenses $38.2M, including $35M Innovent upfront payment
Expert Statements
Esther Rajavelu, President and Chief Executive Officer of Spero Therapeutics
“We believe SP001 represents a compelling opportunity to address significant unmet medical needs across multiple immune-mediated diseases. With a strong financial position and the recent additions to our team that strengthen the capabilities needed to support our next stage of development, we believe we are well positioned to execute our clinical development strategy”
Esther Rajavelu, President and Chief Executive Officer of Spero Therapeutics
“Our focus is now firmly on execution as we advance SP001 toward a Phase 2 study in IgG4-related disease, while continuing to evaluate additional indications where CD40L inhibition may benefit patients.”
* SP001, an anti-CD40L antibody with potential across multiple immune-mediated diseases, advancing toward Phase 2 initiation in Immunoglobulin G4-related disease (IgG4-RD) * Cash and cash equivalents of $107.9 million as of September 30, 2026, expected to fund operations into the second half of 2029 CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for immune-mediated diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.
“We believe SP001 represents a compelling opportunity to address significant unmet medical needs across multiple immune-mediated diseases. With a strong financial position and the recent additions to our team that strengthen the capabilities needed to support our next stage of development, we believe we are well positioned to execute our clinical development strategy,” said Esther Rajavelu, President and Chief Executive Officer of Spero. “Our focus is now firmly on execution as we advance SP001 toward a Phase 2 study in IgG4-related disease, while continuing to evaluate additional indications where CD40L inhibition may benefit patients.”
Get started
Create a free account to read the full story.